A new treatment for multiple myeloma called melflufen (PEPAXTO®) was recently FDA-approved for relapsed or refractory multiple myeloma patients who have received at least four prior lines of therapy. Join us to hear Dr. Agne Paner of Rush University explain what the new therapy is, who qualifies for it, when it should be considered and how it works. Come with questions for the Q&A!
Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.
Dr. Paner is an Associate Professor of Medicine in the Multiple Myeloma and Amyloidosis Program at Rush Medical College. Her research interests include clinical trials with innovative approaches to the treatment of patients with multiple myeloma and amyloidosis. She had hands-on experience in the HORIZON trial. She has been treating multiple myeloma for over 10 years and takes care of about 200 patients with multiple myeloma a year.
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
+1 800 709 1113